
Quanterix Corp — Investor Relations & Filings
Quanterix Corporation is a company focused on digitizing biomarker analysis to advance the science of precision health. Its core offering is the proprietary Simoa® technology, an ultra-sensitive digital immunoassay platform designed to detect and measure biomarkers at extremely low concentrations. This capability allows researchers to study the biology of health and disease with high precision, enabling earlier disease detection, improved prognoses, and the development of more effective treatment methods. The Simoa platform is utilized across a wide range of therapeutic areas, including a strategic focus on neurology (neurodegeneration, neuroinflammation, traumatic brain injuries), as well as oncology, cardiology, inflammation, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | |
| ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | |
| 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41998200 | 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | ||
| 36127788 | ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 36127820 | DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 33034998 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | ||
| 32968563 | 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32968562 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32892834 | 10-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892833 | 8-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892832 | 4 - QUANTERIX CORP (0001503274) (Filer) | 2026-02-18 | English | ||
| 30191110 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30191109 | 4 Filing | 2026-02-06 | English | ||
| 30191105 | 4 Filing | 2026-01-21 | English | ||
| 30191104 | 3 Filing | 2026-01-21 | English | ||
| 30191111 | 4 Filing | 2026-01-20 | English | ||
| 30191086 | 4 Filing | 2026-01-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
Quanterix Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33531/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33531 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33531 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33531 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33531}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Quanterix Corp (id: 33531)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.